Aspen Neuroscience Stock
Aspen Neuroscience is a biotechnology company that uses innovative genomic approaches combined with stem cell biology.
Sign up today and learn more about Aspen Neuroscience Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Aspen Neuroscience Stock
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It develops enabling technologies for patient-specific induced pluripotent stem cell-based therapies.
Funding History
| December 2019 | $6.5M |
|---|---|
| April 2020 | $70.0M |
| May 2022 | $148M |
Management
Co-Founder & Chief Scientific Officer
Jeanne Loring
Board Member, Seed Investor
Drew Spaventa
Chief Scientific Officer
Xiaokui Zhang
Chairman of the Board
Faheem Hasnain
Investor
Afif Khoury
Board Member
Thomas Daniel
Board Member
Doug Fisher
CFO
Kameel Farag
SVP, Research and Development
Andres Bratt-Leal
Board Member
Peter Thompson
Press
prnewswire - Oct, 9 2023
Aspen Neuroscience to Present at 2023 Cell & Gene Meeting on the Mesaprn - Dec, 21 2022
Aspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bankbiospace - Oct, 20 2022
CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officersdbj - May, 23 2022
Aspen Neuroscience Raises $147.5M in Series Bsocaltech - May, 10 2022
Aspen Neuroscience Scores $147.5M Morefiercebiotech - May, 10 2022
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closesprnewswire - Nov, 18 2021
Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officerprnewswire - Nov, 9 2021
Industry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officersdbn - Aug, 4 2020
Aspen Neuroscience Announces Management Transitionmedcitynews - Apr, 12 2020
Funding roundup: At-home medical exams and a Parkinson’s treatmentTechCrunch - Apr, 1 2020
Aspen Neuroscience raises $70M for its experimental Parkinson Disease treatmentEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
